USD/CAD Price Forecast: Consolidates near 1.4250 as rising oil prices counter bullish USD
The USD/CAD pair attracts some sellers during the first half of the European session on Thursday, though it lacks follow-through and currently trades around mid-1.4200s, nearly unchanged for the day. Moreover, spot prices remain within striking distance of the highest level since April 2025, touched earlier this week, amid a bullish US Dollar (USD).
The US Federal Reserve's (Fed) hawkish stance, along with elevated US bond yields and geopolitical uncertainties, helps the safe-haven USD to stand firm near an 18-month high. However, the risk of a further escalation of tensions in the Middle East provides a goodish lift to crude oil prices, underpinning the commodity-linked Loonie and acting as a headwind for the USD/CAD pair.
From a technical perspective, the recent range-bound price action witnessed over the past week or so could still be categorized as a bullish consolidation phase against the backdrop of a strong rally from the September monthly swing low. Meanwhile, the Relative Strength Index (RSI) at 52.7 hints at neutral momentum rather than overbought conditions. Furthermore, the Moving Average Convergence Divergence (MACD) indicator stays marginally below zero, suggesting that bullish pressure is moderating rather than reversing decisively.
Hence, any corrective pullback could find decent support near last Friday's low, around the 1.4200 round figure, which, if broken, might prompt some technical selling and drag the USD/CAD pair to the 1.4150-1.4145 region. On the top side, bulls might now await a move beyond the year-to-date high, around the 1.4300 neighborhood, touched on Monday, before positioning for an extension of a well-established short-term uptrend.
USD/CAD 4-hour chart
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Morgan Stanley senior bond investor turns bullish on US Treasuries for the first time in ten years
US Stock Movement | SuperX AI Technology (SUPX.US) once fell more than 2.5%, hitting an intraday low of $6.46
SuperX AI Technology's stock price declined, falling more than 2.5% at one point.
BUZZ-Pacira BioSciences participated in a Viatris acquisition deal worth 1.65 billions dollars
Latest Update October 8 – Pacira BioSciences (PCRX.O) shares surged by 44%, hitting a more than three-year high at $36.30. If the rally holds, PCRX is poised for its largest single-day gain on record. Pharmaceutical company Viatris (VTRS.O) will acquire Pacira BioSciences in a $1.65 billion cash deal, offering $36.50 per share. The offer represents a premium of approximately 44.8% over Pacira’s recent closing price of $25.20. The transaction will add Pacira’s non-opioid pain medications Exparel and Zilretta to Viatris' product portfolio. Viatris shares fell 2.6% to $17.04. JPMorgan stated: “We believe this acquisition will not significantly alter VTRS' overall financial profile in the short or long term, and expect Exparel’s sales to gradually decline post-2030 due to generic market entry.” Both parties expect to complete the transaction by the end of 2026. Including intraday fluctuations, PCRX shares have risen 40.2% year-to-date, while VTRS has gained 36.8%. (For the convenience of non-English speakers, Reuters provides automated translations of its reports into several other languages. As automated translation may contain errors or lack the necessary context, Reuters does not guarantee the accuracy of automated translated texts and provides them for readers’ convenience only. Reuters assumes no liability for any damage or losses resulting from the use of automated translation.)
Crypto prices
More
